Learn More About The 2026 Summit
Click to explore all of our content related to the 2026 event.
Why In Vivo Might be the Biggest Paradigm Shift for Cell and Gene Therapies
In vivo cell engineering and in vivo gene editing have rapidly transformed from early scientific concepts into the most-watched frontier in cell and gene therapy.
Why Ex Vivo Companies Can’t Afford to Ignore the Future of In Vivo Therapies
For over a decade, ex vivo platforms have shaped the foundational breakthroughs in cell and gene therapy.
How Asia’s IIT Ecosystem Is Accelerating In Vivo Clinical Development in 2026
For in vivo pipeline companies, Asia’s rapidly evolving IIT environment is redefining how early clinical data, manufacturing partnerships, and global strategy come together.
Benchmarking Your In Vivo Pipeline for 2026: Clinical Signals, Asia IIT Acceleration and What Top Biotechs Are Prioritizing Now
Companies with active in vivo pipelines face a different set of pressures than those still exploring the space.
From Early Bet to Market Leader: The In Vivo CAR-T Opportunity
If you have been tracking the advanced therapies landscape recently, it has been hard to miss the growing momentum behind in vivo CAR‑T.
Who Is Betting on In Vivo Approaches
The 5th In Vivo Cell Engineering & Gene Editing Summit will gather 50+ cell and gene therapy decision-makers in Boston this July. See who is planning on attending here.
Stefanos Theoharis, CEO of OneChain Immunotherapeutics Shares Views on In Vivo Cell Therapy
Stefanos Theoharis of OneChain Therapeutics explains why in vivo CAR-T could reshape cell therapy and what breakthroughs still need to happen before it goes mainstream.
Explore the 2026 Full Program
View the detailed agenda, featured speakers, session highlights, and networking opportunities shaping the fastest‑growing frontier in cell and gene therapy.
Secure Your Place
Join the only meeting dedicated to accelerating in vivo cell engineering and gene editing. Connect with global leaders, access exclusive clinical insights for first-in-human trials, and strengthen your development and delivery strategies.
Showcase Your Capabilities
Position your organization in front of senior R&D and CMC decision-makers at the forefront of this growing field. Attendees are seeking CDMOs, CROs, and vector design expertise to scale their in vivo programs.